Enfuvirtide drug interactions
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sophia Saad, Associate Editor – WikiDoc [2]
drug interactions
drug interactions
Potential for FUZEON to Affect Other Drugs
Based on the results from an in vitro human microsomal study, enfuvirtide is not an inhibitor of CYP450 enzymes. In an in vivo human metabolism study (N=12), FUZEON at the recommended dose of 90 mg twice daily did not alter the metabolism of CYP3A4, CYP2D6, CYP1A2, CYP2C19 or CYP2E1 substrates.
Potential for Other Drugs to Affect Enfuvirtide
Based on the available data, co-administration of FUZEON and other drugs which are inducers or inhibitors of CYP450 is not expected to alter the pharmacokinetics of enfuvirtide. No dose adjustments are needed when FUZEON is co-administered with other antiretroviral and non-antiretroviral drugs.[1]
References
References
- ↑ “FUZEON (ENFUVIRTIDE) KIT [GENENTECH, INC.]”. Retrieved 9 January 2014.
Adapted from the FDA Package Insert.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH